Last updated July 4, 2026
Key finding
Estimated treatment difference between 16 and 2 mg was -3.4 kg (-6.0 to -0.8; P = 0.011)
This study evaluated the effects of higher doses of semaglutide on glucose levels in type 2 diabetes patients, finding modest additional benefits at higher doses.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of higher doses of semaglutide on glucose levels in type 2 diabetes patients, finding modest additional benefits at higher doses.
Understanding the effects of semaglutide at varying doses is crucial for optimizing diabetes management. While weight loss is beneficial for type 2 diabetes patients, the lack of significant improvement in glucose control at higher doses suggests that clinicians should consider individual patient responses when prescribing semaglutide.
Specific results for several assessed outcomes were not reported. The study's findings may not be generalizable to all populations with type 2 diabetes. The sample size and demographic characteristics of participants were not detailed.
Published in
Publication details and source links for this paper.
Vanita RA, Nils BJ, Bharath K, Ildiko L, Anne SL, John BB. Higher Semaglutide Doses Provide Modest Additional Glucose-Lowering Effect in Type 2 Diabetes. Diabetes Care. 2025;48(6):905-913. doi:10.2337/dc24-2425
Body weight decreased by an estimated 3.4 kg with the 16 mg dose compared to the 2 mg dose (P = 0.011).
No significant change in HbA1c levels was observed between the 16 mg and 2 mg doses (P = 0.245).
Treatment-emergent adverse events were more frequent in the higher dose groups.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Semaglutide and Adverse events incidence, Body weight, C-reactive protein, and 6 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
5
Related topics
9
Evidence pairs
953
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Semaglutide → Adverse events incidence
Semaglutide → Adverse events incidence
Semaglutide → Diastolic blood pressure
Semaglutide → Diastolic blood pressure
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
11 results
9 results
11 results
11 results
9 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 32 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Blood Pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Systolic blood pressure
EvidenceScore™ Strong | EvidenceScore™ 78.5 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Diastolic blood pressure
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Severe hypoglycemia
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
